GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PH-10 overview

PH-10 is under development for the treatment of mild to moderate plaque psoriasis, atopic dermatitis and skin inflammation. The drug candidate is administered topically. PH-10 is an aqueous hydrogel formulation of rose bengal disodium of 0.005 percent. Rose Bengal is a small molecule agent. PH-10 targets abnormal or diseased cells. The drug candidate undergoes photochemical reactions when activated by ambient light.

It was also under development for the treatment of acne vulgaris, actinic keratosis.

Provectus Biopharmaceuticals overview

Provectus Biopharmaceuticals (Provectus) is a developer of pharmaceuticals for oncology and dermatology indications compmay. The company offers pipeline products such as PV-10 for locally advanced cutaneous melanoma, PV-10 for metastatic liver cancer and PV-10 for neuroendocrine tumors [NET], pediatric solid tumors and other tumors. It also involve in developing a new class of drugs based on halogenated xanthenes such as Rose Bengal. Provectus also offers PH-10 for psoriasis and atopic dermatitis. The company conducts research on ongoing clinical trials for indications including breast cancers, melanoma, head and neck cancers, basal cell carcinoma and squamous cell carcinoma. Provectus is headquartered in Knoxville, Tennessee, the US.

For a complete picture of PH-10’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

Smarter leaders trust GlobalData